Pharmacogenomics - It's not just pharmacogenetics

Current Opinion in Biotechnology

Volumn 9, Issue 6, 1998, Pages 595-601

  Bailey, David S ^a   Bondar, Alexander ^a   Furness, L Mike ^a  

^a Pharmacogenomics Division   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFIBRATE; CLOFIBRATE; DEXAMETHASONE; DIMETHYLNITROSAMINE; DOPAMINE; FENOFIBRATE; GEMFIBROZIL; LIAROZOLE; MEVINOLIN; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PIRINIXIC ACID; TACROLIMUS; VALPROIC ACID; VOMITOXIN;

BIOTECHNOLOGY; DNA SEQUENCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0032402838     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(98)80136-5     Document Type: Article

References (59)

1. Fields C, Adams MD, White O, Venter JC. How many genes in the human genome? Nat Genet. 7:1994;345-346.
2. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
3. Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science. 259:1993;946-951.
4. Bernard K, Auphan N, Granjeaud S, Victorero G, Schmitt-Verhulst AM, Jordan BP, Nguyen C. Multiplex messenger assay: simultaneous, quantitative measurement of expression of many genes in the context of T cell activation. Nucleic Acids Res. 24:1996;1435-1442.
5. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, Hwang SY, Brown PO, Davis RW. Yeast microarrays for genome wide parallel genetic and gene expression analysis. of outstanding interest Proc Natl Acad Sci USA. 94:1997;13057-13062 A key reference showing the practicality of whole genome expression screening using microarrays. This platform uses direct deposition of DNA macromolecules on a glass slide as the hybridisation matrix, and is very flexible in both manufacture and application.
6. Cho RJ, Fromont-Racine M, Wodicka L, Feierbach B, Stearns T, Legrain P, Lockhart DJ, Davis RW. Parallel analysis of genetic selections using whole genome oligonucleotide arrays. of outstanding interest Proc Natl Acad Sci USA. 95:1998;3752-3757 Another key reference showing genome-wide use of microarray technology, in this case using photolithography to produce synthetic oligonucleotide hybridisation matrices in situ on silicon chips.
7. Alak AM. Measurement of tacrolimus and its metabolites. Ther Drug Monit. 19:1997;338-351.
8. Bowers LD. Analytical advances in detection of performance-enhancing compounds. Clin Chem. 43:1997;1299-1304.
9. Marshall A, Hodgson J. DNA chips: an array of possibilities. Nat Biotechnol. 16:1998;27-31.
10. Ramsay G. DNA chips: state-of-the art. Nat Biotechnol. 16:1998;40-44.
11. Woolley AT, Sensabaugh GF, Mathies RA. High-speed DNA genotyping using microfabricated capillary array electrophoresis chips. Anal Chem. 69:1997;2181-2186.
12. Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H, Galibert F, Hoheisel JD, Jacq C, Johnston M, et al. Life with 6000 genes. Science. 274:1996;563-567.
13. Winzeler EA, Richards DR, Conway AR, Goldstein AL, Kalman S, McCullogh MJ, McCusker JH, Stevens DA, Wodicka L, Lokhart DJ, Davis RW. Direct allelic variation scanning of the yeast genome. of special interest Science. 281:1998;1194-1197 This paper illustrates the use of array technology for rapid genetic screening of organisms with simple genomes, such as yeast. The ability to link genetic variation directly to phenotypic information in these systems will lay the foundation for functional genomics and pharmacogenetics in more complex genetic systems, such as the human.
14. Dujon B. European Functional Analysis Network (EUROFAN) and the functional analysis of the Saccharomyces cerevisiae genome. Electrophoresis. 19:1998;617-624.
15. SGD: Saccharomyces Genome Database on World Wide Web URL: http://genome-www.stanford.edu/Saccharomyces/.
16. E. coli Genome Database on World Wide Web URL: http://www.genetics.wisc.edu/.
17. Gray NS, Wodicka L, Thunnissen A-MWH, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. of outstanding interest Science. 281:1998;533-538 An illustration of the integration of chemical library and gene expression profiling approaches to new lead discovery and optimisation. This paper demonstrates the potential leverage to be gained by linkage combinatorial biology to combinatorial chemistry.
18. Davila JC, Rodriguez RJ, Melchert RB, Acosta D. Predictive value of in vitro model systems in toxicology. of special interest Ann Rev Pharmacol Toxicol. 38:1998;63-96 A comprehensive review of current opinions on the use of in vivo systems for predictive toxicology, with emphasis on a number of key applications, which may serve as systems for predicting toxicity in more complex in vivo systems, including human toxicity monitoring.
19. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARα). of outstanding interest J Biol Chem. 273:1998;5678-5684 An excellent and comprehensive paper showing the changes in liver gene and protein expression induced by a pharmacological compound, with interpretation aided by deployment of a transgenic animal model.
20. Sina JF. Predictive toxicology: an overview. of special interest Annu Rep Med Chem. 33:1998;283-291 A brief review of new approaches to exploratory toxicology and their application to drug development.
21. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol. 31:1993;857-907.
22. Linder MW, Prough RA, Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 43:1997;254-266.
23. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 91:1991;631-634.
24. Wang DG, Fan J-B, Siao C-J, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. of outstanding interest Science. 280:1998;1077-1082 An informative paper discussing mapping and genotyping of SNPs from a region of the human genome, illustrating the practicality and utility of 'SNP scanning' and underlining the commercial potential of this area.
25. Phenylalanine Hydroxylase Mutations Database on World Wide Web URL: http://www.mcgill.ca/pahdb/pahmol/oldidx.htm of outstanding interest.
26. A web site containing information on phenylalanine hydroxylase mutations and their biological effects. A great amount of data presented in an easily comprehensible format.
27. Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, Ullrich K, Hoffmann GF, Burgard P, Schmidt H. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet. 63:1998;71-79.
28. Cytochrome P450 Drug Interaction Table on World Wide Web URL: http://www.dml.georgetown.edu/depts/pharmacology/davetab.html.
29. Bailey DS, Johnston GI. Impact of genomics on the discovery and development of modern medicines. of special interest Day INM, Humphries SE. Genetics of Common Disease. 1997;241-262 Bios Scientific Publishers, Oxford, A general introduction to the use of genomics in the pharmaceutical industry.
30. Fannon MR. Gene expression in normal and disease states - identification of therapeutic targets. Trends Biotechnol. 14:1996;294-298.
31. 1998 PhRMA Report on World Wide Web URL: http://www.phrma.org.
32. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol. 45:1993;1563-1569.
33. Leung LK, Glauert HP. Effect of the peroxisome proliferator ciprofibrate on hepatic cyclooxygenase and phospholipase A2 in rats. Toxicology. 126:1998;65-73.
34. Yaacob NS, Norazmi MN, Kass GE, Gibson GG. Use of competitive RT-PCR in the molecular analysis of peroxisome proliferation. Eur J Drug Metab Pharmacokinet. 22:1997;321-324.
35. Suzuki R, Suruga K, Goda T, Takase S. Peroxisome proliferator enhances gene expression of cellular retinol-binding protein, type II in Caco-2 cells. Life Sci. 62:1998;861-871.
36. Waxman DJ, Sundseth SS, Srivastava PK, Lapenson DP. Gene-specific oligonucleotide probes for alpha, mu, pi and microsomal rat glutathione S-transferases: analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs. Cancer Res. 52:1992;5797-5802.
37. Zheng H, Berman NE, Klaassen CD. Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem Int. 27:1995;43-58.
38. Runge-Morris M. Regulation of sulfotransferase gene expression by glucocorticoid hormones and xenobiotics in primary rat hepatocyte culture. Chem Biol Interact. 109:1995;315-327.
39. Bhattacharjee A, Lappi VR, Rutherford MS, Schook LB. Molecular dissection of dimethylnitrosamine (DMN)-induced hepatotoxicity by mRNA differential display. Toxicol Appl Pharmacol. 150:1995;186-195.
40. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci. 18:1998;5301-5310.
41. Staels B, Peinado-Onsurbe J, Auwerx J. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim Biophys Acta. 1123:1992;227-230.
42. Albet S, Causeret C, Bentejac M, Mandel JL, Aubourg P, Maurice B. Fenofibrate differentially alters expression of genes encoding ATP-binding transporter proteins of the peroxisomal membrane. FEBS Lett. 405:1997;394-397.
43. Staels B, Van Tol A, Fruchart JC, Auwerx J. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Isr J Med Sci. 32:1996;490-498.
44. Schoonjans K, Staels B, Grimaldi P, Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric acid derivatives, feeding and liver proliferation. Eur J Biochem. 216:1993;615-622.
45. Corton JC, Bocos C, Moreno ES, Merritt A, Cattley RC, Gustafsson JA. Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes. Biochimie. 79:1997;151-162.
46. Kocarek TA, Reddy AB. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 24:1996;1197-1204.
47. Elliott WH, May BK, Bawden MJ, Hansen AJ. Regulation of genes associated with drug metabolism. Biochem Soc Symp. 55:1989;13-27.
48. Frueh FW, Zanger UM, Meyer UA. Extent and character of phenobarbital-mediated changes in gene expression in the liver. Mol Pharmacol. 51:1997;363-369.
49. Bennett GD, Lau F, Calvin JA, Finnell RH. Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia. 38:1997;415-423.
50. Shikata H, Utsumi N, Shimojima T, Oda Y, Okada Y. Increased expression of type VI collagen genes in drug-induced gingival enlargement. FEBS Lett. 334:1993;65-68.
51. Bruynseels J, De Coster R, Van Rooy P, Wouters W, Coene MC, Snoeck E, Raeymaekers A, Freyne E, Sanz G, Vanden Bussche G, et al. R 75251, a new inhibitor of steroid biosynthesis. Prostate. 16:1990;345-357.
52. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation. 64:1997;1829-1837.
53. Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD. Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet. 70:1997;303-311.
54. Zhou HR, Yan D, Pestka J. Differential cytokine mRNA expression in mice after oral exposure to the trichothecene vomitoxin (deoxynivalenol): dose response and time course. Toxicol Appl Pharmacol. 144:1997;294-305.
55. Meyer U, Zanger UM. Molecular mechanisms of geneticpolymorphisms of drug metabolism. of outstanding interest Ann Rev Pharmacol Toxicol. 37:1997;269-296 A good, in-depth, summary of the known pharmacogenetic mechanisms at play in drug metabolism enzymes, and their population effects.
56. Propping P, Nothen MM. Genetic variation of CNS receptors - a new perspective for pharmacogenetics. Pharmacogenetics. 5:1995;318-325.
57. Kopin AS, McBride EW, Gordon MC, Quinn SM, Beinborn M. Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc Natl Acad Sci USA. 94:1997;11043-11048.
58. Preuss CV, Wood TC, Szumlanski CL, Raftogianis RB, Otterness DM, Girard B, Scott MC, Weinshlboum RM. Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol. 53:1998;708-717.
59. Ljist L, Mandel H, Oostheim W, Ruiter JPN, Gutman A, Wanders RJA. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. J Clin Invest. 102:1998;527-531.